Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Improving the accuracy of blood pressure measuring devices in Australia: a modelled return on investment study
Journal of Human Hypertension, Year 2023
Notification
URL copied to clipboard!
Description
The VALID BP project was initiated to increase the availability of validated blood pressure measuring devices (BPMDs). The goal is to eliminate non validated BPMDs and minimise over- and underdiagnosis of hypertension caused by inaccurate readings. This study was undertaken to assess the potential return on investment in the VALID BP project. The Framework to Assess the Impact of Translational Health Research was applied to the VALID BP project. This paper focuses on the implementation of the cost benefit analysis aspect of this framework to monetise past research investment and model future research costs, implementation costs, and benefits. Analysis was based on reasoned assumptions about potential impacts from availability and use of validated BPMDs (assuming an end goal of 100% validated BPMDs available in Australia by 2028) and improved skills leading to more accurate BP measurement. After 5 years, with 20% attribution of benefits, there is a potential $1.14–$1.30 return for every dollar spent if the proportion of validated BPMDs and staff trained in proper BP measurement technique increased from 20% to 60%. After eight years (2020–2028) and assuming universal validation and training coverage, the returns would be between $2.70 and $3.20 per dollar spent (not including cost of side effects of unnecessary medication or downstream patient impacts from unmanaged hypertension). This modelled economic analysis indicates there will be positive downstream economic benefits if the availability of validated BPMDs is increased. The findings support ongoing efforts toward a universal regulatory framework for BPMDs and can be considered within more detailed future economic analyses. © 2023, The Author(s).
Authors & Co-Authors
Sharman, James E.
Australia, Hobart
University of Tasmania
Schutte, Aletta E.
Australia, Sydney
Unsw Sydney
Delles, Christian
United Kingdom, Glasgow
University of Glasgow
Olsen, Michael Hecht
Denmark, Odense
Syddansk Universitet
Orduń̃ez, Pedro Ovidio
United States, Washington, D.c.
Pan American Health Organization
Hure, Alexis Jayne
Australia, Callaghan
University of Newcastle, College of Health, Medicine and Wellbeing
Morton, Rachael L.
Australia, Sydney
The University of Sydney
Figtree, Gemma A.
Australia, Sydney
The University of Sydney
Webster, Jacqui L.
Australia, Sydney
The University of Sydney
Australia, Sydney
George Institute for Global Health
Jennings, Garry L.R.
Australia, Sydney
The University of Sydney
Australia, Clayton
Monash University
Redfern, Julie
Australia, Sydney
The University of Sydney
Australia, Sydney
George Institute for Global Health
Nicholls, Stephen J.
Australia, Clayton
Monash University
Statistics
Authors: 12
Affiliations: 11
Identifiers
Doi:
10.1038/s41371-023-00866-2
ISSN:
09509240
Research Areas
Health System And Policy
Noncommunicable Diseases